You are here: Industry Insights > Treatment

News List

Bertilimumab Granted Orphan Drug Designation for the Treatment of Bullous Pemphigoid pharmafocusasia
August 22, 2018
Immune Pharmaceuticals, Inc., a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation
PHE data shows link between cancer diagnosis route and treatment pharmatimes
August 17, 2018
Public Health England (PHE) has revealed new data showing that the way that cancer patients are diagnosed can affect their treatment options.
New Treatment for Non-Hodgkin Lymphoma Approved drugs
August 09, 2018
Poteligeo (mogamulizumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with two types of non-Hodgkin lymphoma.
Study demonstrates new treatment for severe asthma worldpharmanews
June 05, 2018
Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton
New Rabies Test Could Radically Change Testing, Treatment drugs
May 17, 2018
A new rapid rabies test for animals could revolutionize screening and spare humans unnecessary painful treatment, according to a U.S. Centers for Disease Control and Prevention study published online May 16 in PLOS ONE.
Orchard Therapeutics’ OTL-200 Receives Rare Pediatric Disease Designation from FDA for Treatment of Metachromatic Leukodystrophy b3cnewswire
May 08, 2018
Orchard Therapeutics, a leading commercial stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies...
To treat pain, you need to treat the patient worldpharmanews
May 08, 2018
People in chronic pain are some of the most difficult patients to treat. They have complex circumstances that medicine can't always remedy.
FDA Green Lights Anika's Injectable HA-Based Bone Repair Treatment biospace
December 28, 2017
Anika Announces FDA 510(k) Clearance for Its Injectable HA-Based Bone Repair Treatment
FDA Approves Treatment for Rare Genetic Enzyme Disorder americanpharmaceuticacreview
November 17, 2017
The FDA is requiring the manufacturer to conduct a post-marketing study to evaluate the long-term safety of the product.
Sangamo Announces Treatment of First Patient in SB-913 Trial americanpharmaceuticacreview
November 16, 2017
All three of Sangamo's in vivo genome editing product candidates have received Fast Track and Orphan Drug designations from the U.S.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page